Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of BBT-877 in Idiopathic Pulmonary Fibrosis
2022-001414-18Phase 2Completed
- Sponsor
- Bridge Biotherapeutics
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of LCB17-0877 in idiopathic pulmonary fibrosis (IPF) (3 arms), sponsored by Bridge Biotherapeutics. Started Dec 2022; status: completed.
02
Drugs
LCB17-0877
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on 2022-001414-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001414-18.